UY31041A1 - Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales para usar en enfermedades mediadas por brca - Google Patents
Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales para usar en enfermedades mediadas por brcaInfo
- Publication number
- UY31041A1 UY31041A1 UY31041A UY31041A UY31041A1 UY 31041 A1 UY31041 A1 UY 31041A1 UY 31041 A UY31041 A UY 31041A UY 31041 A UY31041 A UY 31041A UY 31041 A1 UY31041 A1 UY 31041A1
- Authority
- UY
- Uruguay
- Prior art keywords
- combination
- antiestrogens
- diseases
- brca
- steroid
- Prior art date
Links
- 229940046836 anti-estrogen Drugs 0.000 title abstract 3
- 239000000328 estrogen antagonist Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 229960003387 progesterone Drugs 0.000 title 1
- 239000000186 progesterone Substances 0.000 title 1
- -1 4-acetylphenyl Chemical group 0.000 abstract 3
- 229940123788 Progesterone receptor antagonist Drugs 0.000 abstract 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 2
- 102000036365 BRCA1 Human genes 0.000 abstract 1
- 108700020463 BRCA1 Proteins 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 abstract 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 abstract 1
- 229950004203 droloxifene Drugs 0.000 abstract 1
- 229950002248 idoxifene Drugs 0.000 abstract 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
- 229960002367 lasofoxifene Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229960004622 raloxifene Drugs 0.000 abstract 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 229960005026 toremifene Drugs 0.000 abstract 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Combinacion del antagonista del receptor de progesterona 11B-(4-acetilfenil)-17B-hidroxi-17a-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona, o un derivado o un análogo de éste aceptable para uso farmacéutico, con al menos un antiestrogeno no esteroidal, y uso de dicha combinacion para la profilaxis y el tratamiento de enfermedades mediadas por BRCA1 o BRCA2. Los antiestrogenos no esteroidales que pueden combinarse con el antagonista del receptor de progesterona 11B-(4-acetilfenil)-17B-hidroxi-17a-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona son, por ejemplo, tamoxifeno, raloxifeno, droloxifeno, toremifeno, lasofoxifeno, arzoxifeno, GW5638, EM-800, idoxifeno y basedoxifeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07090082 | 2007-04-23 | ||
| US91438507P | 2007-04-27 | 2007-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31041A1 true UY31041A1 (es) | 2008-11-28 |
Family
ID=39495863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY31041A UY31041A1 (es) | 2007-04-23 | 2008-04-22 | Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales para usar en enfermedades mediadas por brca |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080268041A1 (es) |
| EP (1) | EP2148680A1 (es) |
| JP (1) | JP2010524998A (es) |
| AR (1) | AR066231A1 (es) |
| CA (1) | CA2684084A1 (es) |
| CL (1) | CL2008001147A1 (es) |
| PE (1) | PE20090734A1 (es) |
| TW (1) | TW200904450A (es) |
| UY (1) | UY31041A1 (es) |
| WO (1) | WO2008128792A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703810B2 (en) | 2010-06-10 | 2014-04-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| NZ538346A (en) * | 2000-10-18 | 2007-03-30 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| DK1326617T3 (da) * | 2000-10-18 | 2006-12-18 | Schering Ag | Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeom |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
-
2008
- 2008-04-18 US US12/105,357 patent/US20080268041A1/en not_active Abandoned
- 2008-04-21 WO PCT/EP2008/003335 patent/WO2008128792A1/en active Application Filing
- 2008-04-21 CA CA002684084A patent/CA2684084A1/en not_active Abandoned
- 2008-04-21 JP JP2010504552A patent/JP2010524998A/ja active Pending
- 2008-04-21 EP EP08735387A patent/EP2148680A1/en not_active Withdrawn
- 2008-04-22 CL CL2008001147A patent/CL2008001147A1/es unknown
- 2008-04-22 PE PE2008000690A patent/PE20090734A1/es not_active Application Discontinuation
- 2008-04-22 UY UY31041A patent/UY31041A1/es not_active Application Discontinuation
- 2008-04-22 TW TW097114651A patent/TW200904450A/zh unknown
- 2008-04-22 AR ARP080101667A patent/AR066231A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR066231A1 (es) | 2009-08-05 |
| WO2008128792A1 (en) | 2008-10-30 |
| TW200904450A (en) | 2009-02-01 |
| EP2148680A1 (en) | 2010-02-03 |
| PE20090734A1 (es) | 2009-07-23 |
| CL2008001147A1 (es) | 2008-11-03 |
| US20080268041A1 (en) | 2008-10-30 |
| JP2010524998A (ja) | 2010-07-22 |
| CA2684084A1 (en) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20078326A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
| AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| CO2022014137A2 (es) | Inhibidores de rip1k | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| AR051904A1 (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) | |
| UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
| ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
| BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
| CU20130050A7 (es) | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida | |
| BR112021016861A2 (pt) | Inibidor de interação proteína-proteína wdr5 à base de anilina, método para preparar o mesmo e uso do mesmo | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| CO2023000051A2 (es) | Inhibidores de rip1k | |
| CL2010001471A1 (es) | Un compuestos 2-fluoro-11-(piperazin-1.il) dibenzo´1,4 tiazepina, inhibidores net y antagonista moderado d2; procedimiento de preparacion del mismo; composicion farmaceutica; y uso en el tratamiento de trastornos psiquiatricos, entre otras enfermedades.. | |
| UY31041A1 (es) | Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales para usar en enfermedades mediadas por brca | |
| BRPI0811478B8 (pt) | compostos de morfinano, composição contendo os ditos compostos, usos dos mesmos, embalagem e formas de dosagem separadas | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| AR044450A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| PA8777501A1 (es) | Combinación de antagonista del receptor de progesterona con antiestrógenos no esteroidales para usar en enfermedades mediadas por brca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20171005 |